Biosimilar sponsors have a better shot at getting the US Supreme Court to decide whether they must wait until after FDA approval to provide 180-day notice of intent to launch their products now that they have the backing of the Solicitor General.
On Dec. 7, Acting Solicitor General Ian Gershengorn submitted a brief encouraging the court to grant Sandoz...